In addition to receiving an upfront payment of $1m, which includes $500,000 in cash and $500,000 in equity shares at a 50% premium investment, Dyax is eligible for up to $2m in regulatory and commercialization milestones.
Dyax will also receive royalties equal to 41% of net sales of product, less cost of goods sold.
Consistent with the previous agreement, Sigma-Tau will pay the costs associated with regulatory approval and commercialization in these additional territories.
Dyax president and CEO Gustav Christensen said that expanding the agreement with Sigma-Tau Group enables us to advance the global commercialization strategy for Kalbitor and to make it available to HAE patients worldwide.